Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 22, 2026—Grifols launched at the International Society of Blood Transfusion Congress (Kuala Lumpur, Malaysia, June 20–24) the Evanzys IH, a modular, fully automated, track-enabled system designed to streamline operations and reduce manual intervention in immunohematology sample processing.
June 19, 2026—Proscia introduced the fifth generation of its Concentriq platform, the most significant advancement to the platform in five years.
June 18, 2026—The FDA has granted 510(k) clearance for Diazyme Laboratories’ Lipoprotein(a) Molarity assay.
June 15, 2026—Roche received FDA approval for the Ventana PTEN (SP218) RxDx assay, a qualitative immunohistochemistry companion diagnostic test for determining PTEN protein loss in tumors of patients with prostate adenocarcinoma.
June 8, 2026—Remote Medical Technologies has achieved SOC 2 type 2 certification.
June 5, 2026—Leica Biosystems has expanded its collaboration with AstraZeneca and Daiichi Sankyo to develop an immunohistochemistry assay and image analysis algorithm specifically for the TROP2 normalized membrane ratio biomarker in non-small cell lung cancer, for use as a research tool only.
June 4, 2026—Waters Corp. announced that the BD Bactec FXI culture system has received FDA 510(k) clearance.
June 3, 2026—Diazyme Laboratories has acquired Carolina Liquid Chemistries Corp., an FDA-registered manufacturer and reseller of chemistry systems and reagents.
June 2, 2026—Sysmex America has introduced the XR-Series, a hematology solution designed to help laboratories deliver fast, reliable results while maintaining efficient workflows.
May 29, 2026—Leica Biosystems, Indica Labs, and Lunit are partnering to develop AI-powered image analysis algorithms.
